

**Media contact:**

Vanessa McDonald  
Ballou PR for Sofinnova  
Tel: +44 (0)754 032 5319  
vanessa@balloupr.com

## **Sofinnova Partners Announces Closing of Sixth Fund for €260 million**

**Paris, France – January 26, 2010** – Sofinnova Partners, a leading European venture capital firm, announced today the closure of its sixth fund, Sofinnova Capital VI, raising €260 million. The closing follows the most successful year in the firm’s history, which included three landmark exits (CoreValve, Fovea and Novoxel), one IPO (Movetis) and eight new investments from Sofinnova Capital VI.

Investors in Sofinnova Capital VI include CDC Entreprises, Industrial & Financial Investments Co., JP Morgan Asset Management, funds advised by Partners Group and Skandia Life Insurance Company.

*“Given the context of the global economy and coupled with our successes during the past 12 months, the closing of our sixth fund is testimony to the fact that our investors recognize our solid investment style and our ability to generate returns, even during turbulent economic times,”* said Denis Lucquin, managing partner of Sofinnova Partners. *“With the successful trade sales of our portfolio companies and the IPO of Movetis, 2009 confirmed that Sofinnova Partners is a major player in backing entrepreneurs and building world leading technology companies. This to us proves that one can make money with European Venture.”*

Sofinnova Capital VI already invested in eight start-ups and spinoffs, in disruptive technologies in healthcare therapeutics, medical devices, green chemistry, in wireless and mobile technologies, all led by experienced entrepreneurs and management. These deals include Celsius X VI II (France/Switzerland), CoAxia, Inc. (USA), Crescendo Biologics Ltd (UK), DNP Green Technology, Inc. (Canada/France), Flexion Therapeutics AG (Switzerland/USA), MD Start (Switzerland), Mydeco (UK) and Sagem Wireless (France).

MVision Private Equity Advisers Limited acted as placement agent and law firm Proskauer Rose LLP acted as Sofinnova Partners’ legal counsel.

###

### **About Sofinnova Partners**

Sofinnova Partners is an independent venture capital firm based in Paris, France. For over 35 years, the firm has backed nearly 500 companies at different stages of development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe’s key entrepreneurs in the technology, life sciences and cleantech sectors. With €1.1 billion of funds under management, Sofinnova Partners’ experienced team and hands-on approach in building portfolio companies through to exit have created market leaders, from landmark historical investments including Genentech, Actelion and Vistaprint to more recent successes such as CoreValve, Novoxel and Fovea. With a global mindset, the firm has a sister organization in San Francisco, California. Please visit [www.sofinnova.fr](http://www.sofinnova.fr) for more information on Sofinnova’s team and portfolio.